A Phase 1 interventional study of Lurbinectedin alone and Lurbinectedin+Itraconazole co-administration in Advanced Solid Tumors, sponsored by PharmaMar. Completed at 2 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-02.
Sponsored by PharmaMar · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Prospective, open-label, two-way crossover, phase Ib drug-drug interaction study in patients with advanced solid tumors
Prospective, open-label, two-way crossover, phase Ib drug-drug interaction study in patients with advanced solid tumors.
The study will include a pre-treatment (screening) phase (within 14 days before the first lurbinectedin or itraconazole administration) followed by a treatment phase consisting of two lurbinectedin cycles, one cycle in combination with itraconazole and one cycle as single agent (in different order depending on the study sequence), and one additional third cycle of lurbinectedin as a single agent for patients who meet the continuation criteria and obtain a clinical benefit after the first two cycles, and then follow-up of adverse events if any.
PharmaMar is the lead sponsor of 50 studies on the registry; 5 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Concomitant diseases/conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sequence 1 (TR) * Cycle 1: Itraconazole + lurbinectedin 0.8 mg/m² * Cycle 2: Lurbinectedin alone 3.2 mg/m² * Cycle 3: Lurbinectedin alone 3.2 mg/m² (optional) PART A The dose of lurbinectedin when given in combination with itraconazole for the initial three patients in Part A will be 0.8 mg/m². In Part A, all patients will receive itraconazole plus lurbinectedin in Cycle 1 and lurbinectedin alone in Cycles 2 and 3 (this last cycle being optional). PART B Randomization will apply for study Part B only. In Part B is susceptible to be adjusted properly if deemed necessary based on exposure and safety experience in Part A. In Part B, patients will be randomly assigned to the corresponding sequences.
Drug: Lurbinectedin alone · Drug: Lurbinectedin+Itraconazole co-administration
Sequence 2 (RT): * Cycle 1: Lurbinectedin alone 3.2 mg/m² * Cycle 2: Itraconazole + lurbinectedin 0.8 mg/m² * Cycle 3: Lurbinectedin alone 3.2 mg/m² (optional)
Drug: Lurbinectedin alone · Drug: Lurbinectedin+Itraconazole co-administration
The dose of lurbinectedin during Parts A and B will be 3.2 mg/m² for all patients when administered without itraconazole.
Drug pages: PM 01183 · Itraconazole
The dose of lurbinectedin when given in combination with itraconazole for the initial three patients in Part A will be 0.8 mg/m², and in Part B is susceptible to be adjusted properly if deemed necessary based on exposure and safety experience in Part A.
Pharmacokinetic Analysis: Dose-adjusted AUC(0-∞)
The primary parameter of interest for the statistical analysis will be plasma dose adjusted AUC(0-∞)
Time frame: Day 1, 2, 3, 5, 8, 11, 15, 22 (Cycle 1,2,3) (each cycle is 21 days)
Pharmacokinetic Analysis: Dose-normalized AUC(0-t)
The dose-normalized area under the concentration-time curve (AUC) will be calculated using the linear-log trapezoidal rule with extrapolation to infinity.
Time frame: Day 1, 2, 3, 5, 8, 11, 15, 22 (Cycle 1,2,3) (each cycle is 21 days)
Pharmacokinetic Analysis: Dose-normalized Cmax
The maximum dose-normalized plasma concentration (Cmax) will be obtained directly from the experimental data.
Time frame: Day 1, 2, 3, 5, 8, 11, 15, 22 (Cycle 1,2,3) (each cycle is 21 days)
Pharmacokinetic Analysis: T1/2
Terminal half-life (T1/2) will be obtained from the terminal rate constant calculated by linear regression using at least 3 observations.
Time frame: Day 1, 2, 3, 5, 8, 11, 15, 22 (Cycle 1,2,3) (each cycle is 21 days)
Pharmacokinetic Analysis: Total Body Clearance (CL)
Total body clearance (CL), calculated by dividing the administered dose by the AUC with extrapolation to infinity.
Time frame: Day 1, 2, 3, 5, 8, 11, 15, 22 (Cycle 1,2,3) (each cycle is 21 days)
Pharmacokinetic Analysis: Volume of Distribution
Volume of distribution (both at steady state and based on the terminal phase) (Vss and Vz, respectively): Vss is an estimate that equals mean residence time times total body clearance. Vz, calculated dividing the administered dose by the product of the AUC with extrapolation to infinity by the terminal rate constant
Time frame: Day 1, 2, 3, 5, 8, 11, 15, 22 (Cycle 1,2,3) (each cycle is 21 days)
14 patients were included and treated at 2 sites: 3 in Part A in Sequence 1 (S1 TR: ITZ+lurbinectedin in Cycle 1) and 11 in Part B, of them 5 in S1 and 6 in Sequence 2 (S2 RT: ITZ+lurbinectedin in Cycle 2). In Part A, all patients were assigned to S1 TR, while in Part B, patients were randomly assigned at a 1:1 ratio to S1 TR or S2 RT. Patients participated between 7Oct2020 and 3Mar2022 (last follow-up). The 1st dose of the 1st cycle on 15Oct2020. The last dose of the last cycle on 7Feb2022.
| Milestone | Part A - S1 (TR) | Part B - S1 (TR) | Part B - S2 (RT) |
|---|---|---|---|
| Started | 3 | 5 | 6 |
| Completed | 0 | 0 | 0 |
| Not completed | 3 | 5 | 6 |
| Withdrew: Progressive disease | 2 | 0 | 3 |
| Withdrew: Compassionate use | 1 | 3 | 3 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
The primary parameter of interest for the statistical analysis will be plasma dose adjusted AUC(0-∞)
| μg·h/L/mg | ITZ+LRB | LRB Alone |
|---|---|---|
| Pharmacokinetic Analysis: Dose-adjusted AUC(0-∞) | 288.55 ± 73.9 | 105.8 ± 77.37 |
The dose-normalized area under the concentration-time curve (AUC) will be calculated using the linear-log trapezoidal rule with extrapolation to infinity.
| μg·h/L/mg | ITZ+LRB | LRB Alone |
|---|---|---|
| Pharmacokinetic Analysis: Dose-normalized AUC(0-t) | 244.77 ± 91.89 | 103.4 ± 78.85 |
The maximum dose-normalized plasma concentration (Cmax) will be obtained directly from the experimental data.
| μg/L/mg | ITZ+LRB | LRB Alone |
|---|---|---|
| Pharmacokinetic Analysis: Dose-normalized Cmax | 25.91 ± 53.15 | 22.43 ± 53.75 |
Terminal half-life (T1/2) will be obtained from the terminal rate constant calculated by linear regression using at least 3 observations.
| hours | ITZ+LRB | LRB Alone |
|---|---|---|
| Pharmacokinetic Analysis: T1/2 | 101.36 ± 61 | 46.59 ± 17.12 |
Total body clearance (CL), calculated by dividing the administered dose by the AUC with extrapolation to infinity.
| L/h | ITZ+LRB | LRB Alone |
|---|---|---|
| Pharmacokinetic Analysis: Total Body Clearance (CL) | 3.47 ± 73.9 | 9.45 ± 77.37 |
Volume of distribution (both at steady state and based on the terminal phase) (Vss and Vz, respectively): Vss is an estimate that equals mean residence time times total body clearance. Vz, calculated dividing the administered dose by the product of the AUC with extrapolation to infinity by the terminal rate constant
| L | ITZ+LRB | LRB Alone |
|---|---|---|
| Pharmacokinetic Analysis: Volume of Distribution | 418.68 ± 111.45 | 419.14 ± 58.58 |
Collected over Three 21-days cycles. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ITZ+LRB Cycle | 1/13 (7.7%) | 4/13 (30.8%) | 12/13 (92.3%) |
| LRB Alone Cycle | 1/14 (7.1%) | 5/14 (35.7%) | 13/14 (92.9%) |
| Event | ITZ+LRB Cycle | LRB Alone Cycle |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 1/13 | 1/14 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/13 | 1/14 |
| Small intestinal obstructionGastrointestinal disorders | 1/13 | 1/14 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 1/13 | 1/14 |
| Intestinal obstructionGastrointestinal disorders | 1/13 | 1/14 |
| Deep vein thrombosisVascular disorders | 0/13 | 1/14 |
| Event | ITZ+LRB Cycle | LRB Alone Cycle |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 7/13 | 7/14 |
| NauseaGastrointestinal disorders | 5/13 | 5/14 |
| VomitingGastrointestinal disorders | 4/13 | 4/14 |
| FatigueGeneral disorders | 4/13 | 4/14 |
| ConstipationGastrointestinal disorders | 1/13 | 1/14 |
| Bone painMusculoskeletal and connective tissue disorders | 1/13 | 1/14 |
| DysgeusiaNervous system disorders | 1/13 | 1/14 |
| SyncopeNervous system disorders | 1/13 | 1/14 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/13 | 1/14 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/13 | 1/14 |
| Age, Categorical(Participants) | Part A - S1 (TR) | Part B - S1 (TR) | Part B - S2 (RT) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 3 | 4 | 8 |
| >=65 years | 2 | 2 | 2 | 6 |
| Age, Continuous(years) | Part A - S1 (TR) | Part B - S1 (TR) | Part B - S2 (RT) | Total |
|---|---|---|---|---|
| Median | 69 (49 to 72) | 64 (56 to 70) | 62 (56 to 72) | 63 (49 to 72) |
| Sex: Female, Male(Participants) | Part A - S1 (TR) | Part B - S1 (TR) | Part B - S2 (RT) | Total |
|---|---|---|---|---|
| Female | 3 | 2 | 4 | 9 |
| Male | 0 | 3 | 2 | 5 |
| Race/Ethnicity, Customized(Participants) | Part A - S1 (TR) | Part B - S1 (TR) | Part B - S2 (RT) | Total |
|---|---|---|---|---|
| White | 3 | 5 | 6 | 14 |
| Region of Enrollment(participants) | Part A - S1 (TR) | Part B - S1 (TR) | Part B - S2 (RT) | Total |
|---|---|---|---|---|
| Spain | 3 | 5 | 6 | 14 |
| ECOG PS(Participants) | Part A - S1 (TR) | Part B - S1 (TR) | Part B - S2 (RT) | Total |
|---|---|---|---|---|
| 0 | 1 | 4 | 5 | 10 |
| 1 | 2 | 1 | 1 | 4 |
| Weight(kg) | Part A - S1 (TR) | Part B - S1 (TR) | Part B - S2 (RT) | Total |
|---|---|---|---|---|
| Median | 58.9 (49.9 to 73.9) | 66.6 (50.0 to 102.9) | 69.5 (62.8 to 90.5) | 67.5 (49.9 to 102.9) |
| Height(cm) | Part A - S1 (TR) | Part B - S1 (TR) | Part B - S2 (RT) | Total |
|---|---|---|---|---|
| Median | 165 (159 to 171) | 163 (152 to 172) | 166.5 (153 to 182) | 165 (152 to 182) |
11 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2020 to primary completion in Apr 2022, 18 months.
Results were first posted in Sep 2025, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: PM 01183 · Itraconazole